Endocrinology · Acromegaly

Decoding Your Lab Results and Tumor Type

At a Glance

Acromegaly is usually evaluated with an age-adjusted IGF-1 test and, when needed, a glucose drink test to see whether growth hormone falls. MRI locates a pituitary tumor, while tissue testing describes its subtype and growth clues.

Confirming a diagnosis of acromegaly is more complex than a single blood draw. Because growth hormone (GH) is naturally released in “pulses” throughout the day and night, a random GH test is often misleading and insufficient for diagnosis ^[1]^[2]. A single “normal” GH reading does not rule out the disease, just as a single “high” reading doesn’t confirm it ^[3]. Instead, doctors use a multi-step biochemical process to understand exactly what your hormones are doing.

The Two Pillars of Biochemical Diagnosis

To confirm the hormone excess of acromegaly, medical teams look for two specific signals in your blood:

Age-Adjusted IGF-1: This is usually the first test performed. Unlike GH, IGF-1 (Insulin-like Growth Factor-1) levels are stable throughout the day ^[1]. However, “normal” IGF-1 levels change significantly as you age. Your result must be compared against a reference range specifically for your age and sex. A clearly elevated level is a strong indicator of acromegaly ^[1]^[4].
The Oral Glucose Tolerance Test (OGTT): If IGF-1 is high or borderline, an OGTT may be used to confirm that the excess hormone production is autonomous (acting on its own) ^[5]. You will drink a standard 75-gram glucose (sugar) solution, and your GH levels will be measured over the next two hours ^[5]. In a person without acromegaly, the sugar should “turn off” GH production, causing it to drop (often below 0.4 µg/L, depending on the specific lab assay used) ^[4]^[6]. If your GH fails to drop (suppress), it confirms the excess GH production ^[4].

Note that the OGTT confirms the hormone excess but does not locate the tumor. A pituitary MRI is needed to confirm the presence of a pituitary adenoma. Furthermore, the OGTT is not always strictly necessary if your IGF-1 is unequivocally elevated and the diagnosis is clear.

Understanding Your Tumor Subtype

If you have surgery to remove the tumor, a pathologist will examine the tissue under a microscope. Not all GH-secreting tumors are the same; they generally fall into different patterns that can help predict their behavior.

Feature	Densely Granulated Somatotroph Tumor	Sparsely Granulated Somatotroph Tumor
Growth Pattern	Usually slower-growing and less likely to invade nearby structures rapidly ^[7]	Often larger and more likely to be invasive ^[8]
MRI Appearance	Tends to be T2-hypointense (appears darker on specific MRI scans) ^[9]	Tends to be T2-hyperintense (appears brighter on specific MRI scans) ^[10]
Medication Response	Often responds better to first-line medications (octreotide/lanreotide) ^[7]	May be less responsive to first-line drugs; might lead to consideration of other medications ^[11]

These associations are probabilistic, meaning they provide clues but do not absolutely guarantee how your tumor will respond to a specific medication.

The Pathology Checklist (Optional Details)

When you receive your pathology report after surgery, it may contain specific details that help your endocrinologist understand your tumor. These are findings that may be integrated by your team, not guarantees of treatment response:

Lineage Markers: Confirmation of the PIT-1 protein, which identifies the cells as belonging to the growth hormone family ^[12].
Granulation Pattern: Whether the tumor is densely or sparsely granulated ^[13].
Receptor Status: In some centers, staining for SSTR2 (Somatostatin Receptor Type 2) or SSTR5 is performed to predict your response to injections, though this is not universally required ^[14].
Ki-67 Index: A percentage that measures how fast the tumor cells are dividing. A higher Ki-67 (such as above 3%) might suggest a faster growth pattern, but it must be interpreted alongside your clinical symptoms and MRI ^[13]^[15].

Note: Your MRI and the surgeon’s operative report will detail whether the tumor has invaded nearby structures, like the cavernous sinus. This is typically a clinical and imaging finding, rather than something strictly determined by a pathologist under a microscope ^[16].

Common questions in this guide

Can a normal random growth hormone result rule out acromegaly?

No. Growth hormone is released in pulses, so one normal random result may miss excess production, while one high result does not prove acromegaly. Doctors usually rely on age-adjusted IGF-1 and, when needed, a glucose suppression test.

What does an elevated IGF-1 result mean in acromegaly?

An elevated IGF-1 compared with the reference range for your age and sex is a strong sign of acromegaly. IGF-1 is usually the first blood test used, but your clinician interprets it with your symptoms and other results.

How does the glucose drink test help confirm acromegaly?

During an oral glucose tolerance test, you drink 75 grams of glucose and growth hormone is measured for about two hours. In people without acromegaly, glucose usually lowers growth hormone; failure to suppress supports excess production. The exact cutoff depends on the laboratory assay.

Does the oral glucose test show where the pituitary tumor is?

No. The test evaluates whether growth hormone suppresses after glucose and confirms hormone excess, but it does not locate a tumor. A pituitary MRI is used to look for a pituitary adenoma and assess invasion, such as involvement of the cavernous sinus.

What is the difference between densely and sparsely granulated somatotroph tumors?

Densely granulated tumors are often slower-growing, appear darker on T2 MRI, and respond better to octreotide or lanreotide. Sparsely granulated tumors are often larger or more invasive, appear brighter on T2 MRI, and may respond less to those medicines. These are general patterns, not guarantees.

What do PIT-1, SSTR2, SSTR5, and Ki-67 mean on a pathology report?

PIT-1 helps confirm the tumor's growth hormone cell lineage, while granulation describes its cell pattern. SSTR2 and SSTR5 staining may provide clues about response to injectable medicines, and Ki-67 estimates how quickly cells are dividing. These findings must be interpreted with MRI and clinical information.

Curated prompts to bring to your next appointment.

1.My IGF-1 is [Value]; how does this compare to the age-adjusted normal range for my specific age and gender?
2.During my OGTT, what was the lowest growth hormone (nadir) level reached, and which assay sensitivity was used for the 0.4 µg/L cutoff?
3.Does my MRI show a T2-hypointense or T2-hyperintense tumor, and how might this affect our choice of first-line medication?
4.Can you review my pathology report to see if SSTR2 and SSTR5 staining were performed, and do we need them?
5.Is my tumor considered 'densely granulated' or 'sparsely granulated,' and what does that mean for my long-term prognosis?
6.What was my Ki-67 index, and does it suggest a more aggressive growth pattern?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (16)

1
Consensus on criteria for acromegaly diagnosis and remission.
Giustina A, Biermasz N, Casanueva FF, et al.
Pituitary 2024; (27(1)):7-22 doi:10.1007/s11102-023-01360-1.
PMID: 37923946
2
The Biochemical Diagnosis of Acromegaly.
Akirov A, Masri-Iraqi H, Dotan I, Shimon I
Journal of clinical medicine 2021; (10(5)) doi:10.3390/jcm10051147.
PMID: 33803429
3
Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment.
Campana C, Cocchiara F, Corica G, et al.
The Journal of clinical endocrinology and metabolism 2021; (106(3)):789-801 doi:10.1210/clinem/dgaa859.
PMID: 33236108
4
Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey.
de Pablos-Velasco P, Venegas EM, Álvarez Escolá C, et al.
Pituitary 2020; (23(2)):129-139 doi:10.1007/s11102-019-01012-3.
PMID: 31823249
5
Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism?
Dobri G, Niwattisaiwong S, Bena JF, et al.
Endocrine 2019; (64(1)):139-146 doi:10.1007/s12020-018-1805-z.
PMID: 30415402
6
Acromegaly diagnosis.
Yogi-Morren D, Chanson P
The Journal of clinical endocrinology and metabolism 2026; (111(Supplement_1)):S38-S50 doi:10.1210/clinem/dgag189.
PMID: 42056759
7
Clinical and prognostic significance of granulation patterns in somatotroph adenomas/tumors of the pituitary: a meta-analysis.
Vuong HG, Dunn IF
Pituitary 2023; (26(6)):653-659 doi:10.1007/s11102-023-01353-0.
PMID: 37735314
8
Pathological Classification and Clinical Characteristics of Growth Hormone-Secreting PitNETs.
Li Z, Wu Y, Gao Y, et al.
Neuroendocrinology 2026; 1-16 doi:10.1159/000552989.
PMID: 42348504
9
Analysis of Diffusion-Weighted and T2-Weighted Imaging in the Prediction of Distinct Granulation Patterns of Somatotroph Adenomas.
Tang Y, Xie T, Guo Y, et al.
World neurosurgery 2024; (182()):e334-e343 doi:10.1016/j.wneu.2023.11.107.
PMID: 38052365
10
Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences.
Potorac I, Petrossians P, Daly AF, et al.
Endocrine-related cancer 2015; (22(2)):169-77 doi:10.1530/ERC-14-0305.
PMID: 25556181
11
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study.
Iacovazzo D, Carlsen E, Lugli F, et al.
European journal of endocrinology 2016; (174(2)):241-50 doi:10.1530/EJE-15-0832.
PMID: 26586796
12
Imaging of pituitary tumors: an update with the 5th WHO Classifications-part 2. Neoplasms other than PitNET and tumor-mimicking lesions.
Tsukamoto T, Miki Y
Japanese journal of radiology 2023; (41(8)):808-829 doi:10.1007/s11604-023-01407-0.
PMID: 36913010
13
Overview of the 2017 WHO Classification of Pituitary Tumors.
Mete O, Lopes MB
Endocrine pathology 2017; (28(3)):228-243 doi:10.1007/s12022-017-9498-z.
PMID: 28766057
14
Expression of somatostatin receptor subtype 2 in growth hormone-secreting pituitary adenoma and the regulation of miR-185.
Fan X, Mao Z, He D, et al.
Journal of endocrinological investigation 2015; (38(10)):1117-28 doi:10.1007/s40618-015-0306-7.
PMID: 26036598
15
Clinical Implications of the New WHO Classification 2017 for Pituitary Tumors.
Saeger W, Koch A
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2021; (129(3)):146-156 doi:10.1055/a-1310-7900.
PMID: 33690870
16
Growth hormone secreting pituitary carcinomas: Case report and review of literature.
Vekaria S, Chen F, Zan E, et al.
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2021; (60-61()):101430 doi:10.1016/j.ghir.2021.101430.
PMID: 34607164

This page explains acromegaly testing and pituitary tumor pathology for informational purposes only and does not constitute medical advice. Ask your endocrinologist and care team to interpret your results and guide treatment.

Get notified when new evidence is published on growth hormone-producing pituitary gland neoplasm.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents